Nevertheless, continued research on the orphan nuclear receptor NR2F6 represents a suitable path for drug discovery and might offer an innovative, mechanism-based, therapeutic strategy to augment the sensitivity of tumor-infiltrating T cells to tumor antigens in cancer patients. The gene discussed is ESRRB; the disease is cancer.